| Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles J Kattan, JP Droz, P Couvreur, JP Marino, A Boutan-Laroze, P Rougier, ... Investigational new drugs 10, 191-199, 1992 | 186 | 1992 |
| Evaluating the impact of spirituality on the quality of life, anxiety, and depression among patients with cancer: an observational transversal study EA Chaar, S Hallit, A Hajj, R Aaraj, J Kattan, H Jabbour, LR Khabbaz Supportive Care in Cancer 26, 2581-2590, 2018 | 131 | 2018 |
| Antitrust analysis of technology joint ventures: allocative efficiency and the rewards of innovation J Kattan Antitrust LJ 61, 937, 1992 | 103 | 1992 |
| Efficiencies and merger analysis J Kattan Antitrust LJ 62, 513, 1993 | 84 | 1993 |
| FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer M Ghosn, F Farhat, J Kattan, F Younes, W Moukadem, F Nasr, G Chahine American journal of clinical oncology 30 (1), 15-20, 2007 | 73 | 2007 |
| Penile cancer chemotherapy: twelve years' experience at Institut Gustave-Roussy J Kattan, S Culine, JP Droz, E Fadel, B Court, JL Perrin, P Wibault, ... Urology 42 (5), 559-562, 1993 | 69 | 1993 |
| The growing teratoma syndrome: a woman with nonseminomatous germ cell tumor of the ovary J Kattan, JP Droz, S Culine, P Duvillard, A Thiellet, C Peillon Gynecologic oncology 49 (3), 395-399, 1993 | 67 | 1993 |
| Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial TE Witzig, K Tobinai, L Rigacci, T Ikeda, A Vanazzi, M Hino, Y Shi, ... Annals of Oncology 29 (3), 707-714, 2018 | 65 | 2018 |
| Market power in the presence of an installed base J Kattan Antitrust LJ 62, 1, 1993 | 64 | 1993 |
| Non-small cell lung cancer brain metastases and the immune system: from brain metastases development to treatment E El Rassy, A Botticella, J Kattan, C Le Péchoux, B Besse, L Hendriks Cancer treatment reviews 68, 69-79, 2018 | 63 | 2018 |
| Adult Wilms' tumour: review of 22 cases J Kattan, MF Tournade, S Culine, MJ Terrier-Lacombe, JP Droz European Journal of Cancer 30 (12), 1778-1782, 1994 | 61 | 1994 |
| Revealing a cancer diagnosis to patients: attitudes of patients, families, friends, nurses, and physicians in Lebanon—results of a cross-sectional study F Farhat, A Othman, G El Baba, J Kattan Current Oncology 22 (4), 264-272, 2015 | 54 | 2015 |
| Do checkpoint inhibitors compromise the cancer patients’ immunity and increase the vulnerability to COVID-19 infection? J Kattan, C Kattan, T Assi Immunotherapy 12 (6), 351-354, 2020 | 53 | 2020 |
| The therapeutic use of human albumin in cancer patients’ management E Moujaess, M Fakhoury, T Assi, H Elias, F El Karak, M Ghosn, J Kattan Critical reviews in oncology/hematology 120, 203-209, 2017 | 52 | 2017 |
| A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu–negative metastatic breast cancer FS Farhat, S Temraz, J Kattan, K Ibrahim, N Bitar, N Haddad, R Jalloul, ... Clinical breast cancer 11 (6), 384-389, 2011 | 51 | 2011 |
| Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients M Ghosn, J Kattan, F Farhat, F Younes, J Gasmi Anticancer research 26 (3B), 2451-2456, 2006 | 48 | 2006 |
| Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: a comprehensive review T Assi, J Kattan, E Rassy, H Nassereddine, F Farhat, C Honore, ... Critical Reviews in Oncology/Hematology 153, 103029, 2020 | 47 | 2020 |
| Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer FL Nasr, GY Chahine, JG Kattan, FS Farhat, WT Mokaddem, EA Tueni, ... Clinical Breast Cancer 5 (2), 117-122, 2004 | 47 | 2004 |
| Clinical and genetic factors associated with anxiety and depression in breast cancer patients: a cross-sectional study A Hajj, R Hachem, R Khoury, S Hallit, B ElJEBBAWI, F Nasr, F El Karak, ... BMC cancer 21, 1-11, 2021 | 46 | 2021 |
| Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma A Shamseddine, YH Zeidan, Z El Husseini, M Kreidieh, M Al Darazi, ... Radiation Oncology 15, 1-7, 2020 | 46 | 2020 |
